I have opinions about BLSI. First of all, I own some shares...
So far, Altropane is the ONLY thing in the clinic. It had good PD PIII results. ADHD is a longer shot, for reasons Scott and others have noted. Still, PII for ADHD is complete and results are being analyzed.
The other pipeline stuff has been WAY over publicized. The company publishes endless PRs about preclinical candidates. I wish they would just be quiet about them until they actually make it into the clinic.
The company does apparently have close relationships with Mass General Hospital and Harvard Med School. That is somehthing in their favor.
They also recently did a private placement to raise more money. I don't like the way they did it: through a Swiss bank - it is not clear to me what the deal was and who it was with and why the purchasing party was interested. I think there is enough liquidity in the US to support good ideas (especially in Boston for life sciences), so why did BLSI go overseas?
BLSI merged with Greenwich several years ago. Supposedly, now they wish they didn't: apparently Greenwich did not have a very good reputation with the investment community - but, BLSI maintains that there are no common personnel between the old Greenwich and the current BLSI.
But, as you noted, Altropane looks like it will generate some good revenue. If it is approved for ADHD, then it will generate some really great revenue. And their preclinical compounds look promising. I believe they have even partnered up with Pfizer on one of them.
Well, it looks as though I've trashed one of my own holdings! Actually, I think BLSI has promise. I wouldn't buy more myself until seeing more execution - an NDA filed and approved, a marketing partner, another compound in the clinic.
H |
